Dolutegravir 50 MG

Clinical Trial to Evaluate the Efficacy, Pharmacokinetics (PK) Interactions and Safety of Dolutegravir Plus 2 Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in HIV-1-Infected Solid Organ Transplant Patients

Tenofovir-lamivudine-dolutegravir Combination as Second-line ART: a Randomised Controlled Trial

Standard Versus Double Dose Dolutegravir in Patients With HIV-associated Tuberculosis

Pharmacokinetics of Twice or Once Daily DTG (50mg) in Children With HIV and TB

Impact of a Dolutegravir-based Regimen on Early Mortality of AIDS Patients

REal-Life Cohort With DOlutegravir + LAmivudina

Contribution of Dolutegravir to Obesity and Cardiovascular Disease

Effect of Dolutegravir Intensification on HIV-1 Reservoirs

Rapid HIV Treatment Initiation, Access and Engagement in Care

Safety and Efficacy of Fixed Dose Combination Dolutegravir/Abacavir/Lamivudine FDC Initiated During Acute HIV Infection

Efficacy and Safety of a Dolutegravir-based Regimen for the Initial Management of HIV Infected Adults in Resource-limited Settings

Dolutegravir Plus 2 NRTIs, in Treatment-Naïve HIV-2 Infected Subjects

Phase 4 Study of Dolutegravir (DTG) in Russian Federation

A Study to Evaluate the Effects of Calcium Carbonate and Ferrous Fumarate on Pharmacokinetics of Dolutegravir in Healthy Adult Subjects

Evaluation of the Bioequivalence of a Combined Formulated Tablet

Dolutegravir Renal Impairment Study

Relative Bioavailability Study of Two New Dolutegravir/Abacavir/Lamivudine Fixed Dose Combination Tablets